(Q39360781)

11 September 2017

title

Tasquinimod: a novel drug in advanced prostate cancer (English)

1 reference

11 September 2017

1 reference

3

Jacobus Burggraaf

1 reference

11 September 2017

Susanne Osanto

1

1 reference

11 September 2017

Hendrik van Poppel

series ordinal

2

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 September 2013

1 reference

11 September 2017

1 reference

11 September 2017

volume

9

1 reference

11 September 2017

issue

9

1 reference

11 September 2017

page(s)

1271-1281

1 reference

Global patterns of cancer incidence and mortality rates and trends

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Emerging novel therapies for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Alpha emitter radium-223 and survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

S100 chemokines mediate bookmarking of premetastatic niches

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

S100A9 interaction with TLR4 promotes tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

Bioanalysis in clinical development of tasquinimod using liquid chromatography/tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.136

21 January 2018

Identifiers

DOI

10.2217/FON.13.136

1 reference

11 September 2017

1 reference